CD274 and neoplasm: Circulating Tumor DNA (ctDNA) profiles have been evaluated as an early accurate biomarker able to identify pseudoprogressors and differentiate them from true progressors.26, 27 Performing sequential ctDNA tests to patients receiving anti‐PD(L)‐1 agents could represent an alternative to dynamically monitor these patients, although further validation is needed in larger cohorts of patients.